How to Safely Stop Farxiga (Dapagliflozin): A Clinical Discontinuation Protocol

First Identify Why Dapagliflozin Was Prescribed

Dapagliflozin has FDA-labeled uses in type 2 diabetes, chronic kidney disease, and heart failure. A person may have more than one indication. A discontinuation plan that only addresses glucose can therefore miss the reason the drug was being used.

The current June 2026 prescribing information should anchor the decision. The label describes the approved uses, dosing, temporary interruption for surgery, kidney-function considerations, and actions for adverse effects. It does not prescribe one fixed seven-day, four-week, and twelve-week laboratory schedule for every patient.

Does Farxiga Need to Be Tapered?

The current label provides once-daily doses and instructions for withholding or discontinuing dapagliflozin, but it does not specify a gradual taper. The practical safety issue is not a classic withdrawal syndrome. It is the loss of treatment for diabetes, heart failure, or kidney disease and the need to address the reason for stopping.

Do not halve tablets or create an alternate-day schedule unless the prescriber specifically directs it. An elective stop should answer three questions:

1. Which condition or conditions is dapagliflozin treating?
2. Is the interruption temporary or permanent?
3. What monitoring or alternative treatment is needed for each indication?

Situations That Require a Hold or Stop

Suspected Ketoacidosis

The label directs clinicians to assess for ketoacidosis when symptoms or clinical signs suggest it, regardless of the presenting glucose level. If suspected, dapagliflozin should be discontinued, the condition treated promptly, and the patient monitored until it resolves.

Possible symptoms include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Precipitating factors listed in the prescribing information include reduced caloric intake, ketogenic diet, surgery, volume depletion, acute febrile illness, missed or reduced insulin, and pancreatic disorders suggesting insulin deficiency. This is an urgent clinical problem, not a routine medication-taper question.

Planned Surgery or Prolonged Fasting

Before surgery or procedures associated with prolonged fasting, the current label says to withhold dapagliflozin for at least three days when possible. It may be resumed when the patient is clinically stable and has resumed oral intake.

That is a temporary interruption, not necessarily permanent discontinuation. The surgical and prescribing teams should coordinate the exact stop and restart dates, glucose management, and ketone assessment when indicated.

Acute Illness, Dehydration, or Reduced Intake

The label advises withholding dapagliflozin in temporary clinical situations that could predispose to ketoacidosis and resuming when the patient is clinically stable and has resumed oral intake. Volume depletion and acute kidney injury are separate concerns, especially in older adults, people with impaired kidney function, or those using loop diuretics.

Hypersensitivity or Serious Adverse Effects

Serious hypersensitivity is a contraindication. Fournier gangrene, urosepsis, pyelonephritis, and severe genital infections require prompt clinical assessment. Whether the drug is permanently stopped depends on the event and the prescriber’s assessment; the page no longer invents a set number of routine infections as a universal stopping threshold.

What May Change After Long-Term Discontinuation

Type 2 Diabetes

Removing a glucose-lowering drug can raise glucose. The amount and timing depend on baseline control, kidney function, diet, and other medications. There is no evidence-backed universal prediction that fasting glucose will rise by a specific number within 72 hours or that every patient’s HbA1c will rise by the same percentage.

People who monitor glucose should agree on frequency and action thresholds with the prescribing team. Insulin and sulfonylurea changes require particular care because dose adjustments can cause hypoglycemia or hyperglycemia.

Heart Failure

In DAPA-HF, dapagliflozin reduced the composite of worsening heart failure or cardiovascular death in patients with heart failure and reduced ejection fraction (PMID 31535829). That trial establishes the benefit of treatment; it does not establish a universal post-discontinuation NT-proBNP threshold or an automatic diuretic increase.

After stopping, monitoring can include symptoms, blood pressure, and daily weight when already part of the heart-failure plan. Rapid weight gain, increasing swelling, worsening breathlessness, or difficulty lying flat should prompt contact with the heart-failure team. DAPA-HF supports the importance of the therapy but not a fixed post-stop monitoring schedule (PMID 31535829).

Chronic Kidney Disease

DAPA-CKD showed a lower risk of sustained eGFR decline, end-stage kidney disease, or death from renal or cardiovascular causes with dapagliflozin in eligible CKD patients (PMID 32970396). Stopping removes that ongoing therapy; it does not create a predictable “rebound” value for eGFR or albuminuria in every patient.

Kidney-function and potassium testing should be timed to the clinical situation and any replacement therapy. A brief eGFR change after starting or stopping an SGLT2 inhibitor must be interpreted in the context of the longer-term DAPA-CKD evidence rather than labeled kidney recovery or damage from a single value (PMID 32970396).

A Safer Elective-Discontinuation Checklist

Use this as a discussion guide rather than a self-directed protocol:

1. Confirm every indication. Record whether dapagliflozin is being used for diabetes, heart failure, CKD, or more than one.
2. Name the reason for stopping. Distinguish adverse effects, pregnancy, cost or coverage, lack of indication, an acute hold, and personal preference.
3. Review current status. Relevant information can include glucose or HbA1c, kidney function, blood pressure, volume status, heart-failure symptoms, and other medications.
4. Plan ongoing treatment. Decide whether another medication or a change in the existing regimen is needed. Alternatives are indication-specific and are not interchangeable.
5. Set monitoring and action thresholds. The team should specify what will be checked, when, and which symptoms or values warrant contact.
6. Document restart criteria for a temporary hold. For surgery or illness, clarify who will decide when the patient meets the label's restart conditions of clinical stability and resumed oral intake.

Switching Is Not Always Equivalent

Dapagliflozin and empagliflozin share a drug class, but a class-related adverse effect may recur with another SGLT2 inhibitor. Conversely, a formulary change may permit a clinician-directed switch that preserves an indicated class therapy. The reason for stopping determines whether switching is sensible.

EMPEROR-Reduced found that empagliflozin reduced cardiovascular death or hospitalization for heart failure in its trial population (PMID 32865377). That evidence does not make the two drugs automatically interchangeable for every diagnosis, kidney-function range, formulary, or individual.